Pieris Pharmaceuticals: Q3 Earnings Snapshot
Pieris Pharmaceuticals Inc. (PIRS) on Wednesday reported a loss of $2.9 million in its third quarter. On a per-share basis, the Boston-based company said it had a loss of $2.19. This story was generated by Automated Insights ( using data from Zacks Investment Research.
Bluebird bio Inc., which nine years ago was worth nearly as much as the airline JetBlue, said it's now looking for enough ...
William Blair analyst Sami Corwin reiterated a Hold rating on Bluebird Bio (BLUE – Research Report) today. The company’s shares closed today at $0.36. Corwin covers the Healthcare sector, focusing ...
Zacks.com on MSN6d
After Plunging -22.76% in 4 Weeks, Here's Why the Trend Might Reverse for Bluebird (BLUE)Bluebird Bio (BLUE) has been beaten down lately with too much selling pressure. While the stock has lost 22.8% over the past ...
Research analysts at StockNews.com assumed coverage on shares of bluebird bio (NASDAQ:BLUE – Get Free Report) in a research ...
SOMERVILLE, Mass. (AP) — SOMERVILLE, Mass. (AP) — Bluebird Bio Inc. (BLUE) on Thursday reported a loss of $60.8 million in its third quarter. On a per-share basis, the Somerville, Massachusetts-based ...
Zacks.com on MSN17h
Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue EstimatesBluebird Bio (BLUE) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.66 per share a year ago. These figures are ...
On Tuesday, bluebird bio Inc (BLUE) stock saw a decline, ending the day at $0.39 which represents a decrease of $-0.02 or -4.88% from the prior close of $0.41. The stock opened at $0.4 and touched a ...
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported third quarter results and business highlights for the quarter ended September ...
Analysts estimate that bluebird bio will report an earnings per share (EPS) of $-0.37. Anticipation surrounds bluebird bio's announcement, with investors hoping to hear about both surpassing estimates ...
JP Morgan has recently reduced bluebird bio Inc (BLUE) stock to Neutral rating, as announced on August 15, 2024, according to Finviz. Earlier, on December 11, 2023, HSBC Securities had reduced the ...
Bluebird Bio ( (BLUE) ) has issued an announcement. At bluebird bio, Inc.’s 2024 Annual Meeting, key decisions included increasing the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback